[CAS NO. 30462-35-2] Theaflavin 3,3'-digallate
PRODUCTS SPECIFICATIONS [30462-35-2]
DESCRIPTION [30462-35-2]
Overview
| MDL | MFCD06797365 |
|---|---|
| Molecular Weight | 868.70 |
| Molecular Formula | C43H32O20 |
| SMILES | O=C(C1=CC(O)=C(C(O)=C1)O)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C4=C5C(C(C(O)=CC([C@@H]6[C@@H](CC7=C(O)C=C(O)C=C7O6)OC(C8=CC(O)=C(C(O)=C8)O)=O)=C5)=O)=C(C(O)=C4)O |
2 Publications Citing Use of MCE
Summary
Theaflavin 3,3'-digallate (TF-3) is a potent Zika virus (ZIKV) protease inhibitor with an IC 50 of 2.3 μM. Theaflavin 3,3'-digallat directly binds to ZIKVpro ( K d =8.86 µM) and inhibits ZIKV replication. Theaflavin 3,3'-digallat inhibits the activity of gp41 and NS2B-3 protease and has antiviral activity against HSV and HIV-1 [1] . Theaflavin 3,3'-digallate, the typical pigment in black tea, is a potent antitumor agent [2] .
IC50 & Target
|
HSV |
HIV-1 |
In Vitro
Theaflavin 3,3'-digallate (TF-3; 6.25, 12.5, 25 μM; 24 hours) markedly reduces viral RNA copy numbers and NS3, U87 MG protein expression in a dose-dependent manner
[1]
.
Theaflavin 3,3'-digallate inhibits dose-dependently ZIKV replication in Vero E6 cells (EC
50
=7.65 μM). Theaflavin 3,3'-digallate has minor cytotoxicity up to 40 μM in Vero E6 cells. Theaflavin 3,3'-digallate can inhibit the post-entry events of the ZIKV replication cycle from gene transcription and translation levels
[1]
.
Theaflavin 3,3'-digallate is generally regarded as the effective component for the inhibitory effects against carcinogenesis without adverse side effects by affecting multiple signal transduction pathways, such as upregulating p53 and p21, inhibiting phosphorylation of the cell survival protein Akt and MAPK pathway, downregulation of NF-κB, shifting the ratio between pro-/antiapoptotic proteins. Theaflavin 3,3'-digallate causes a rapid and sustained decrease in phospho-ERK1/2 and -MEK1/2 protein expression. Theaflavin 3,3'-digallate inhibits HCT116 cell growth with an IC
50
of 17.26 μM
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Vero E6 cells |
| Concentration: | 6.25, 12.5, 25 μM |
| Incubation Time: | 24 hours |
| Result: | Markedly reduced NS3, U87 MG protein expression in a dose-dependent manner. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03629223 | Merck KGaA, Darmstadt, Germany |
Healthy
|
August 23, 2018 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL ( 115.11 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.1511 mL | 5.7557 mL | 11.5115 mL |
| 5 mM | 0.2302 mL | 1.1511 mL | 2.3023 mL |
| 10 mM | 0.1151 mL | 0.5756 mL | 1.1511 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.88 mM); Clear solution
References
- [1] Xiangling Cui, et al. Identification of Theaflavin-3,3'-Digallate as a Novel Zika Virus Protease Inhibitor. Front Pharmacol. 2020 Oct 21;11:514313.
- [2] Ding Y, et al. Pre-treated theaflavin-3,3'-digallate has a higher inhibitory effect on the HCT116 cell line. Food Nutr Res. 2017 Nov 15;61(1):1400340.
Synonyms